Manuel Montero, MD
Nephrology · New Bern, NCNPI 1114929346
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,264 of the $5,060 with a category attached, or 64.5%. 20 manufacturers reported payments, led by Bayer at 32.3% of the total. Reporting peaked in 2024 at $3,196 and has fallen 82.0% since, to $577 in 2025.
Across 125 payments — averaging $40.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$2K
- AstraZeneca$1K
- Nxstage Medical, Inc.$580
- Amgen$517
- Fresenius USA Marketing, Inc.$287
- Otsuka America Pharmaceutical, Inc.$225
- plus $772 from 14 others
Across 1,784 payments — averaging $1389.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$953K
- Akebia Therapeutics Inc$355K
- Novo Nordisk AS$329K
- Fresenius USA Marketing, Inc.$286K
- AstraZeneca$142K
- Bayer$92K
- plus $321K from 9 others
What the payments were for
- Travel & lodging$1,71334%
- Food & beverage$3,26465%
- Education$822%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 14 | $1,632 |
| AstraZeneca(2 entities) | 13 | $1,047 |
| Nxstage Medical, Inc. | 9 | $580 |
| Amgen(2 entities) | 25 | $517 |
| Fresenius USA Marketing, Inc. | 9 | $287 |
| Otsuka America Pharmaceutical, Inc. | 11 | $225 |
| Vifor Pharma, Inc. | 7 | $115 |
| GSK | 6 | $105 |
| Novartis | 5 | $99 |
| Travere Therapeutics, Inc. | 5 | $63 |
| Ardelyx, Inc. | 3 | $61 |
| Calliditas Therapeutics US Inc. | 2 | $56 |
| Daiichi Sankyo Inc. | 3 | $50 |
| OPKO Pharmaceuticals, LLC | 2 | $39 |
| Novo Nordisk | 2 | $35 |
| Aurinia Pharma U.S., Inc. | 2 | $34 |
| Sanofi | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Akebia Therapeutics Inc | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,060 in reported general payments places this provider in the 75th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 262 | $161,404 |
| VelphoroSucroferric Oxyhydroxide | 23 | $84,290 |
| JardianceEmpagliflozin | 110 | $69,563 |
| AuryxiaFerric Citrate | 18 | $45,116 |
| Sevelamer Carbonate | 23 | $6,127 |
| Midodrine Hcl | 59 | $4,290 |
| Furosemide | 427 | $3,932 |
| Nifedipine ErNifedipine | 133 | $2,360 |
| Losartan Potassium | 258 | $1,486 |
| Metolazone | 25 | $1,314 |
| Potassium Chloride | 91 | $1,295 |
| Amlodipine Besylate | 216 | $735 |
| Hydralazine Hcl | 46 | $682 |
| Bumetanide | 17 | $644 |
| Metoprolol Succinate | 65 | $532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,047 | $161,404262 claims |
| Fresenius USA Marketing, Inc.Velphoro | $287 | $84,29023 claims |
| Boehringer IngelheimJardiance | $31 | $69,563110 claims |
| Akebia Therapeutics IncAuryxia | $30 | $45,11618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 366 nephrology providers in North Carolina.
Other nephrology in New Bern
- Stuart JenningsNew Bern$40K
- Nathan SaucierNew Bern$21K
- Gregory GreenwoodWinston-Salem$947K
- Michael EtomiCharlotte$212K
- William KendrickGreenville$125K
- Jason EckelCary$123K
- Raven VooraSanford$111K
- Nam VoAsheville$89K
- Jennifer StoddardPinehurst$77K
- Barry FreedmanWinston Salem$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.